veltuzumab

A humanized monoclonal antibody directed against the CD20 antigen with potential antineoplastic activity. Following binding, veltuzumab triggers… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2008-2018
051020082018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
A lingering criticism of radioimmunotherapy in non-Hodgkin lymphoma is the use of cold anti-CD20 antibody along with the… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
2014
2014
IMPORTANCE B-cell depletion with the anti-CD20 antibody rituximab is highly effective for pemphigus vulgaris (PV) treatment… (More)
  • figure 1
  • figure 2
Is this relevant?
2011
2011
BACKGROUND Subcutaneous injections of anti-CD20 antibodies may offer benefits to both patients and the healthcare system for… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
PURPOSE This is a multicenter phase I/II dose-finding study in relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL) evaluating… (More)
  • table 1
  • table 1
  • table 2
  • figure 1
  • table 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Veltuzumab is a humanized anti-CD20 monoclonal antibody with complementarity-determining regions (CDRs) identical to rituximab… (More)
  • table 1
  • table 2
Is this relevant?
2009
2009
Veltuzumab is a humanized, second-generation anti-CD20 mAb currently under development by Immunomedics Inc for the potential… (More)
Is this relevant?
2009
2009
The dock and lock (DNL) method is a new technology for generating multivalent antibodies. Here, we report in vitro and in vivo… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2009
2009
Interferon-alpha (IFN-alpha) has direct inhibitory effects on some tumors and is a potent stimulator of both the innate and… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2008
2008
Purpose: Antibodies are effective therapeutic agents in cancer, but cures are rarely if ever obtained. Combination therapies are… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
Is this relevant?
2008
2008
PURPOSE Antibodies are effective therapeutic agents in cancer, but cures are rarely if ever obtained. Combination therapies are… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
Is this relevant?